TMO vs ILMN vs RVTY Stock Comparison

Thermo Fisher Scientific, Illumina and Revvity Prices as of Oct 23, 2026 Peers: Industry group
ILMN Illumina, Inc.
$269.42 +5.5% 1M +169.5% 1Y
Market cap
$40.91B
P/E
49.6x
Revenue (TTM)
$4.49B
Div. yield
–
Life Sciences Tools Healthcare
5 wins
RVTY Revvity, Inc.
$158.70 +11.7% 1M +62.7% 1Y
Market cap
$17.90B
P/E
75.4x
Revenue (TTM)
$2.91B
Div. yield
0.00%
Life Sciences Tools Healthcare

Head to Head

12 decided of 12

Thermo Fisher Scientific leads on 7 of the 12 questions below (Thermo Fisher Scientific 7, Illumina 5). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionTMOILMNRVTYLeader
Larger companyMarket capitalisation $254.18B $40.91B $17.90B TMO
Cheaper on earningsLower P/E, profitable companies only 36.5x 49.6x 75.4x TMO
Cheaper on forward earningsLower price / next fiscal year consensus EPS 26.1x 53.9x 31.1x TMO
Faster revenue growthRevenue growth, trailing twelve months +7.2% +4.9% +4.1% TMO
More profitableNet margin, trailing twelve months 15.0% 18.4% 8.2% ILMN
Better return on capitalReturn on invested capital 7.9% 15.1% 3.1% ILMN
Less leveragedLower net debt / EBITDA 3.5x 0.7x 2.8x ILMN
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% TMO
Better 1-year returnPrice return, last 12 months +17.8% +169.5% +62.7% ILMN
Better 5-year returnAnnualised price return, 5 years +1.9%/yr -7.5%/yr -2.1%/yr TMO
Less volatileAnnualised volatility, 1 year 29.8% 50.3% 39.9% TMO
Higher overall scoreMean of the five percentile scores vs peers 59/100 65/100 58/100 ILMN

Percentile Scorecard

TMOILMNRVTY

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisTMOILMNRVTY
Valuation 60 #93 of 228 52 #111 of 228 69 #72 of 228
Growth 35 #144 of 222 43 #126 of 222 27 #163 of 222
Profitability 83 #37 of 210 97 #7 of 210 79 #46 of 210
Financial Health 28 #174 of 241 51 #118 of 241 47 #128 of 241
Shareholder Returns 88 #18 of 138 84 #23 of 138 68 #45 of 138
Overall 59 65 58
  • TMO ranked among 248 companies in Medical Devices and Diagnostics
  • ILMN ranked among 248 companies in Medical Devices and Diagnostics
  • RVTY ranked among 248 companies in Medical Devices and Diagnostics

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodTMOILMNRVTYSPY
1 month +1.2%+5.5%+11.7% -1.0%
3 months +18.6%+38.8%+43.7% +2.9%
6 months +43.5%+110.7%+82.9% +6.4%
Year to date +16.3%+105.4%+64.0% +11.4%
1 year +17.8%+169.5%+62.7% +13.1%
3 years +47.1%+138.6%+55.8% +79.4%
3 years, per year +13.7%+33.6%+15.9% +21.5%
5 years +10.1%-32.3%-10.0% +67.7%
5 years, per year +1.9%-7.5%-2.1% +10.9%
10 years +347.3%+95.3%+201.2% +255.2%
10 years, per year +16.2%+6.9%+11.7% +13.5%

Risk

MeasureTMOILMNRVTYSPY
Volatility, 1Y 29.8%50.3%39.9% 12.7%
Downside volatility, 1Y 28.3%39.1%35.7% 12.7%
Beta vs S&P 500, 1Y 0.590.801.20 1.00
Return / volatility, 1Y 0.603.371.57 1.03
Max drawdown, 5Y -41.5%-82.9%-59.2% -25.4%
From 52-week high -3.3%-8.3%0.0% -2.5%
52-week high $696.55$293.69$158.70 $779.14
52-week low $438.34$95.03$82.26 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleTMOILMNRVTY
P/E now vs peer median 35.9xmedian 30.7x 49.3xmedian 30.7x 74.5xmedian 30.7x
P/S now vs peer median 5.4xmedian 3.0x 9.1xmedian 3.0x 6.1xmedian 3.0x
EV/EBITDA now vs peer median 25.9xmedian 17.7x 36.0xmedian 17.7x 25.6xmedian 17.7x
P/FCF now vs peer median 34.0xmedian 23.7x 43.7xmedian 23.7x 31.1xmedian 23.7x
P/B now vs peer median 4.7xmedian 2.4x 14.3xmedian 2.4x 2.4xmedian 2.4x
PEG now vs peer median 4.27median 0.96 1.64median 0.96 -2.39median 0.96

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsTMOILMNRVTY
Revenue $46.34B $4.49B $2.91B
Gross profit $18.91B $2.98B $1.60B
Operating income $8.15B $882.00M $358.85M
Net income $6.99B $825.00M $237.55M
Free cash flow $7.32B $931.00M $568.85M
R&D $1.40B $960.00M $215.83M
EPS (diluted) $18.78 $5.39 $2.13
Cash & equivalents $4.06B $1.04B $1.02B
Total debt $42.55B $6.97B $3.21B
Shares (diluted) 371.00M 153.00M 111.63M
Enterprise value $233.20B $35.68B $14.17B

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricTMOILMNRVTY
P/E 35.9x 49.3x 74.5x
P/FCF 34.0x 43.7x 31.1x
P/Operating cash flow 27.6x 37.2x 27.7x
P/S 5.4x 9.1x 6.1x
P/B 4.7x 14.3x 2.4x
P/Tangible book 7.3x 16.8x 3.5x
EV/EBITDA 25.9x 36.0x 25.6x
EV/EBIT 35.3x 47.1x 55.4x
EV/Revenue 6.2x 9.2x 6.8x
EV/FCF 39.3x 44.6x 35.0x
EV/Operating cash flow 31.9x 37.9x 31.2x
PEG (3Y EPS CAGR) 4.27 1.64 -2.39

Growth

14 metrics
MetricTMOILMNRVTY
Revenue growth (1Y) 7.2% 4.9% 4.1%
Revenue CAGR (3Y) 2.1% -1.0% 0.9%
Gross profit growth (1Y) 6.2% 4.6% 2.3%
Gross profit CAGR (3Y) 3.0% 2.9% -0.4%
Operating income growth (1Y) 10.0% -31.8% -5.5%
Operating income CAGR (3Y) 6.7% 28.3% -3.7%
Net income growth (1Y) 6.2% -34.4% -16.7%
Net income CAGR (3Y) 6.9% 30.0% -33.8%
EPS growth (1Y) 7.8% -32.7% -12.3%
EPS CAGR (3Y) 8.4% 30.1% -31.2%
Operating cash flow growth (1Y) 18.9% -5.1% 6.2%
Operating cash flow CAGR (3Y) 5.4% 38.1% 86.9%
Free cash flow growth (1Y) 18.6% -9.7% 9.5%
Free cash flow CAGR (3Y) 7.7% 105.0% 64.8%

Profitability

14 metrics
MetricTMOILMNRVTY
Gross margin 40.8% 66.4% 55.0%
EBITDA margin 23.9% 25.7% 26.6%
Operating margin 17.6% 19.6% 12.3%
Pretax margin 16.5% 22.6% 9.0%
Net margin 15.0% 18.4% 8.2%
FCF margin 15.8% 20.7% 19.5%
Operating cash flow margin 19.5% 24.4% 21.9%
Return on equity 13.4% 29.9% 3.3%
Return on assets 6.2% 12.5% 2.0%
Return on invested capital 7.9% 15.1% 3.1%
Return on capital employed 8.3% 17.5% 3.3%
Asset turnover 0.4x 0.7x 0.2x
Cash conversion (OCF / net income) 1.3x 1.3x 2.7x
Stock comp / revenue 0.7% 5.9% 0.8%

Financial Health

11 metrics
MetricTMOILMNRVTY
Debt / assets 37.6% 29.9% 26.6%
Debt / equity 0.8x 0.7x 0.4x
Net debt / EBITDA 3.5x 0.7x 2.8x
Debt / FCF 5.8x 2.1x 5.6x
Liabilities / assets 53.4% 57.3% 40.0%
Equity / assets 46.6% 42.7% 60.0%
Interest coverage 5.6x 8.9x 3.7x
Current ratio 1.6x 1.8x 1.8x
Quick ratio 1.0x 1.2x 1.4x
Cash ratio 0.3x 0.7x 0.8x
Altman Z-score 3.98 7.73 3.36

Shareholder Returns

7 metrics
MetricTMOILMNRVTY
Dividend yield 0.3% – 0.2%
Net buyback yield 2.0% 1.2% 2.6%
Shareholder yield 2.3% 1.2% 2.8%
Payout ratio (earnings) 9.5% – 13.4%
Payout ratio (FCF) 9.0% – 5.6%
Dividend growth (1Y) 8.5% – -6.3%
Dividend CAGR (3Y) 10.8% – -6.1%

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusTMOILMNRVTY
Forward P/E 26.1xFY2026 53.9xFY2026 31.1xFY2026
EPS, next fiscal year $25.77FY2026 $5.00FY2026 $5.10FY2026
EPS growth, next FY +12.7%FY2026 +3.3%FY2026 +0.8%FY2026
EPS growth, the year after +1.8% +25.4% +11.0%
Revenue, next fiscal year $49.99BFY2026 $4.52BFY2026 $2.98BFY2026
Revenue growth, next FY +12.2%FY2026 +4.1%FY2026 +4.0%FY2026
Revenue growth, the year after -2.9% +12.0% -2.0%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersTMOILMNRVTY
Held by institutions 90.2% 100.0% 100.0%
Institutions holding 2,621 933 545
Change in shares held, QoQ +0.8% +0.0% -1.3%
Institutions buying 1,141 463 301
Institutions selling 1,144 330 161
Buyers to sellers 1.00 1.40 1.87

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

TMOILMNRVTY
TMO 1.00 0.50 0.71
ILMN 0.50 1.00 0.51
RVTY 0.71 0.51 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, TMO, ILMN and RVTY?

Thermo Fisher Scientific (TMO) is the largest by market capitalisation: Thermo Fisher Scientific (TMO) $254.18B, Illumina (ILMN) $40.91B, Revvity (RVTY) $17.90B.

Which stock is cheaper, TMO, ILMN and RVTY?

Thermo Fisher Scientific (TMO) trades on the lowest price-to-earnings ratio (Thermo Fisher Scientific (TMO) 36.5x, Illumina (ILMN) 49.6x, Revvity (RVTY) 75.4x). On next year's consensus earnings, Thermo Fisher Scientific (TMO) is cheapest (Thermo Fisher Scientific (TMO) 26.1x, Illumina (ILMN) 53.9x, Revvity (RVTY) 31.1x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Thermo Fisher Scientific (TMO) grew revenue fastest over the trailing twelve months: Thermo Fisher Scientific (TMO) +7.2%, Illumina (ILMN) +4.9%, Revvity (RVTY) +4.1%.

Which company is more profitable?

Illumina (ILMN) has the highest net margin (Thermo Fisher Scientific (TMO) 15.0%, Illumina (ILMN) 18.4%, Revvity (RVTY) 8.2%). On return on invested capital, Illumina (ILMN) leads (Thermo Fisher Scientific (TMO) 7.9%, Illumina (ILMN) 15.1%, Revvity (RVTY) 3.1%).

Which stock has performed better?

Over the past year Illumina (ILMN) returned the most: Thermo Fisher Scientific (TMO) +17.8%, Illumina (ILMN) +169.5%, Revvity (RVTY) +62.7%. Over five years, Thermo Fisher Scientific (TMO) compounded fastest (Thermo Fisher Scientific (TMO) +1.9%/yr, Illumina (ILMN) -7.5%/yr, Revvity (RVTY) -2.1%/yr). Returns are price only, before dividends.

Which pays a higher dividend?

Thermo Fisher Scientific (TMO) has the highest dividend yield: Thermo Fisher Scientific (TMO) 0.00%, Illumina (ILMN) 0.00%, Revvity (RVTY) 0.00%. Illumina (ILMN) pays no regular dividend.

Which stock is riskier?

By one-year price volatility, Thermo Fisher Scientific (TMO) has been the steadiest (Thermo Fisher Scientific (TMO) 29.8%, Illumina (ILMN) 50.3%, Revvity (RVTY) 39.9%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, TMO, ILMN and RVTY?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Thermo Fisher Scientific (TMO) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.